PMID- 36644881
OWN - NLM
STAT- MEDLINE
DCOM- 20230403
LR  - 20230403
IS  - 1465-3621 (Electronic)
IS  - 0368-2811 (Linking)
VI  - 53
IP  - 4
DP  - 2023 Mar 30
TI  - Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal 
      stromal tumors: comparison of safety and efficacy between standard and reduced 
      dosage regimens.
PG  - 297-303
LID - 10.1093/jjco/hyac202 [doi]
AB  - BACKGROUND: Sunitinib therapy for patients with imatinib-resistant and/or 
      intolerant gastrointestinal stromal tumors (GISTs) often causes severe adverse 
      events (AEs) that lead to treatment discontinuation. METHODS: We retrospectively 
      reviewed the clinical records of imatinib-resistant and/or intolerant GIST 
      patients who underwent sunitinib therapy in our institutions between 2007 and 
      2020. Forty-one patients were enrolled and divided into two groups on the basis 
      of the starting dosage: the standard dosage group (50 mg/day, 21 patients) and 
      the reduced dosage group (37.5 mg/day, 20 patients). Tolerability, safety and 
      clinical efficacy of the two groups were compared. RESULTS: Three patients (14%) 
      in the standard dosage group and another three (15%) in the reduced dosage group 
      (P = 1.000) discontinued sunitinib therapy because of AEs. The incidences of 
      grade 3 or more severe treatment-related AEs were 90 and 75%, respectively 
      (P = 0.238). Two possible treatment-related deaths were noted in the standard 
      dosage group. Clinical efficacy was comparable between the two groups: median 
      time to treatment failure and overall survival were 4.5 months [interquartile 
      range (IQR), 3.6-9.0] and 13.7 months (IQR, 7.5-22.9) in the standard dosage 
      group and 4.6 months (IQR, 2.7-17.0) and 13.4 months (IQR, 9.3-36.8) in the 
      reduced dosage group, respectively. CONCLUSIONS: The reduced dosage of 37.5 mg 
      sunitinib tended to decrease toxicity and the incidences of severe AEs and 
      treatment-related deaths. This reduced dosage regimen showed equivalent clinical 
      efficacy including patient survival. The reduced dosage of 37.5 mg sunitinib can 
      be adopted as an alternative therapy for patients with imatinib-resistant and/or 
      intolerant GISTs.
CI  - (c) The Author(s) 2023. Published by Oxford University Press. All rights reserved. 
      For permissions, please e-mail: journals.permissions@oup.com.
FAU - Sasaki, Kenta
AU  - Sasaki K
AD  - Department of Medical Oncology, Niigata University Graduate School of Medical and 
      Dental Sciences, Niigata, Japan.
AD  - Department of Internal Medicine, Sanjo General Hospital, Sanjo, Japan.
FAU - Kanda, Tatsuo
AU  - Kanda T
AUID- ORCID: 0000-0001-6863-1587
AD  - Department of Surgery, Sanjo General Hospital, Sanjo, Japan.
FAU - Matsumoto, Yoshifumi
AU  - Matsumoto Y
AD  - Department of Medical Oncology, Niigata University Graduate School of Medical and 
      Dental Sciences, Niigata, Japan.
FAU - Ishikawa, Takashi
AU  - Ishikawa T
AD  - Division of Digestive and General Surgery, Niigata University Graduate School of 
      Medical and Dental Sciences, Niigata, Japan.
FAU - Hirota, Seiichi
AU  - Hirota S
AD  - Department of Surgical Pathology, Hyogo Medical University School of Medicine, 
      Nishinomiya, Japan.
FAU - Saijo, Yasuo
AU  - Saijo Y
AD  - Department of Medical Oncology, Niigata University Graduate School of Medical and 
      Dental Sciences, Niigata, Japan.
LA  - eng
GR  - Niigata University/
PT  - Journal Article
PL  - England
TA  - Jpn J Clin Oncol
JT  - Japanese journal of clinical oncology
JID - 0313225
RN  - V99T50803M (Sunitinib)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - 0 (Pyrimidines)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - Sunitinib/therapeutic use
MH  - Imatinib Mesylate/adverse effects
MH  - *Gastrointestinal Stromal Tumors/drug therapy
MH  - Retrospective Studies
MH  - Indoles/adverse effects
MH  - Pyrroles/adverse effects
MH  - Pyrimidines/therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - Treatment Outcome
MH  - *Antineoplastic Agents/adverse effects
OTO - NOTNLM
OT  - GIST
OT  - dosage
OT  - sunitinib
EDAT- 2023/01/17 06:00
MHDA- 2023/04/03 06:41
CRDT- 2023/01/16 04:12
PHST- 2022/06/28 00:00 [received]
PHST- 2022/12/11 00:00 [accepted]
PHST- 2023/04/03 06:41 [medline]
PHST- 2023/01/17 06:00 [pubmed]
PHST- 2023/01/16 04:12 [entrez]
AID - 6987660 [pii]
AID - 10.1093/jjco/hyac202 [doi]
PST - ppublish
SO  - Jpn J Clin Oncol. 2023 Mar 30;53(4):297-303. doi: 10.1093/jjco/hyac202.